| NCT ID | NCT07421219 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vastra Gotaland Region |
| Condition | Non-progressive Congenital Ataxia |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-05-15 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-05-15 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multinational European observational clinical study focuses on non-progressive congenital ataxia (NPCA), a very rare early-onset neurological condition also within the cerebral palsy (CP) concept as ataxic CP. The study aims to improve the diagnosis and care of affected children through a comprehensive approach that integrates detailed clinical assessments, brain imaging analyses, and advanced genetic testing. By identifying developmental trajectories, specific impairment profiles, brain MRI patterns, and genetic variants, the researchers aim to elucidate underlying mechanisms, origins and clinical heterogeneity of NPCA. The study also assesses the broader impact of the condition on the quality of life of affected children and the associated burden on their families. Preliminary data found a high prevalence of cognitive and neuropsychiatric impairments, and a frequent lack of identifiable brain lesions on MRI, raising the hypothesis of a strong genetic contribution.
Eligibility Criteria
Inclusion Criteria: • male or female children * confirmed diagnosis of NPCA/Ataxic CP (SCPE definition) * aged ≥ 5 years and ≤ 8 years at time of data collection * written informed consent of at least one parent or legal representative in accordance to country regulations, and verbal assent of the child when possible Exclusion Criteria: Children with all other diagnoses of movement disorders or other CP subtypes \-
Contact & Investigator
Catherine Arnaud, MD PhD
STUDY DIRECTOR
University Hospital of Toulouse
Frequently Asked Questions
Who can join the NCT07421219 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 8 Years, studying Non-progressive Congenital Ataxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07421219 currently recruiting?
Yes, NCT07421219 is actively recruiting participants. Contact the research team at kate.himmelmann@vgregion.se for enrollment information.
Where is the NCT07421219 trial being conducted?
This trial is being conducted at Leuven, Belgium, Aarhus, Denmark, Toulouse, France, Tübingen, Germany and 3 additional locations.
Who is sponsoring the NCT07421219 clinical trial?
NCT07421219 is sponsored by Vastra Gotaland Region. The principal investigator is Catherine Arnaud, MD PhD at University Hospital of Toulouse. The trial plans to enroll 50 participants.